audeo indicative ipo pricing is now public, page-15

I'm not sure what your on about ginger.

If you have 1000 shares in ACL then they are currently worth $530 at today's price( 1000x0.53). If you get 1 Audeo share for every 37 shares you currently hold in ACL, then you would be allocated 27 shares in Audeo(1000/ 37). If Audeo IPO'd at $15 per share then your shares in Audeo would be valued at $405.

If the price of ACL were to stay at today's level( 0.53) post IPO, and Audeo reached $15- then the Total value of your assets would be increase from $530 to $935.( $530 Audeo+ $405 Oncology)

Remember the current market cap of ACL is 153 million, however at the mid-point of $15, Audeos market cap post IPO would be $162.6 million( Providing it doesn't get over allocated), $114 million of that will be made up of ACL's current shareholders at the record date late next week. If the IPO hits the midpoint then this would mean Fonda's value for current holders in ACL post IPO, would only be seen as 39 million (153- 114), or 0.14 cents(39mil/280mil)... so 0.14 could be seen as the break even point. In other words if Audeo hits $15 and is fully allocated, then after ACL loses i'ts oncology assets, the SP could afford to fall to 0.14 cents before current ACL holders would be worse off following the split. The likely hood of ACL( Fonda) falling to 0.14 cents with a MC of 39 million seems highly unlikely( or more like impossible), in a company that's going to be making anywhere from 20-35 million p/a

The other funny thing for me is that in latest Analyst report posted on ACL's website; Nomura when valuing the company have only attributed a risk weighted average of 35% to Oncology( so 50 million at today's price), and have attributed the other 65%(100 million) To Fonda.

IMO cake we could see a strong rally next week, i'm talking 70 cents +

It's always hard to call with this stock though, and I'd always expected price to reach those kind of levels already- followed by a dumping after the record date...